Chk1 is a serine/threonine protein kinase that is activated by a wide range of DNA-damaging agents to slow the cell cycle during S phase and G2/M. Abrogation of these cellcycle checkpoints using Chk1 inhibitors results in hypersensitivity to DNA-damaging agents in vitro and may provide a potential therapeutic tool to sensitize tumour cells in vivo. We have generated a Cre-Lox-based mouse model in which Chkl can be inducibly deleted from somatic epithelial cells in the adult mouse small intestine and liver. Loss of Chk1 in the liver is tolerated with no apparent phenotype. In contrast, the loss of Chk1 within the small intestine results in immediate DNA damage and high levels of p53-independent apoptosis leading to crypt death. However, the intestine is able to compensate for this death by undergoing complete re-population with Chk1-proficient cells. These data therefore show that Chk1 deficiency is cell lethal, but the intestine can tolerate such lethality at the organ level.
Introduction
Ionizing radiation and many chemotherapeutic agents used in the treatment of cancer induce DNA damage to kill tumour cells. These therapies not only activate apoptotic signalling pathways, but also survival mechanisms such as DNA damage-response pathways and cell-cycle arrest, which allow for DNA repair to occur. DNA damage-induced cell-cycle arrest depends on the activation of an evolutionarily conserved signalling network in which Chk1, a serine/threonine checkpoint kinase, plays a pivotal role (Nyberg et al., 2002; Sancar et al., 2004) . Chk1 is active at the intra-S-phase, G2/M and the spindle checkpoints, and recent study has indicated that abrogation of these checkpoints through the inhibition of Chk1 may be a feasible cancer-cellspecific therapy (Hapke et al., 2001; Bartek and Lukas, 2003; Kawabe, 2004; Tse et al., 2007) . This approach is based on the fact that more than half of human cancer cells have a defective G1 checkpoint due to functional defects in the p53 and Rb pathways (Levine, 1997) . Tumour cells are therefore more reliant than normal cells on the S-phase and G2 checkpoint kinases such as Chk1 to induce cell-cycle arrest in response to DNA damage, to allow DNA repair and prevent cell death. There is now a significant body of in vitro data (Wang et al., 1996; Koniaras et al., 2001; Chen et al., 2003; Xiao et al., 2003; Zachos et al., 2003; Robinson et al., 2006) showing that the disruption of these checkpoints through Chk1 inhibition can sensitize tumour cells to DNA-damaging agents, and thus Chk1 inhibition may well be able to enhance the efficacy of current therapies. However, to validate it as a therapeutic approach, it is essential to establish the biological role of Chk1 in vivo.
Chk1 is essential for mammalian development and viability as Chk1-deficient mice are embryonically lethal due to a peri-implantation defect (Liu et al., 2000; Takai et al., 2000) . Owing to the lethality of the embryonic null mutation, Chk1 has also been studied in two conditional knockout mouse models using the Cre-loxP system (Lam et al., 2004; Zaugg et al., 2007) . In these models, the Chk1 null phenotype was restricted to either the mammary gland or the thymus, and in both cases, the homozygous disruption of the Chk1 alleles resulted in cell death due to an increase in apoptosis (Lam et al., 2004; Zaugg et al., 2007) . An earlier study has also proposed Chk1 as a tumour suppressor and although this hypothesis remains unconfirmed, Lam et al. (2004) have shown that the loss of a single Chk1 allele in the mouse mammary gland results in severe cell-cycle mis-coordination due to checkpoint disruption. The observation that the loss of a single Chk1 allele results in genomic instability has also been suggested by recent study using a Chk1 þ /À WNT-1 transgenic model (Liu et al., 2000) , in which the loss of a single Chk1 allele results in a modest increase in tumour burden, suggesting that Chk1 may act as a haploinsufficient tumour suppressor. However, germline Chk1 þ /À mice have no detectable spontaneous tumour predisposition up to 18 months of age (Liu et al., 2000) , indicating that in isolation, Chk1 haploinsufficiency acts only very weakly as a tumour promoter.
Although our understanding of Chk1 in cell-cycle regulation is becoming clearer, it is still essential that we obtain more information regarding the in vivo consequences of Chk1 loss in somatic cells. For this purpose, we have generated a mouse model in which the Chk1 allele can be conditionally deleted from the mouse small intestine and liver. In this study, we have shown that a loss of both Chk1 alleles results in a rapid induction of intestinal crypt apoptosis. However, the intestine is capable of compensating for such loss, responding with a period of intestinal cell proliferation, by which the intestinal crypts are re-populated with wild-type cells. In contrast, the loss of both Chk1 alleles in the liver appears to be tolerated with no apparent phenotype for a period of up to 9 months.
Results
Chk1 is rapidly but transiently lost in the mouse small intestine following b-naphthoflavone injection To delete Chk1 from the murine small intestine, we crossed mice containing a Chk1 allele in which exon 2 was flanked by loxP sites (Lam et al., 2004) with mice containing a Cre transgene under the control of the CYP1A1 (AhCre) promoter (Ireland et al., 2004) . We have shown earlier that this construct drives highefficiency recombination within the crypt, including the stem cell compartment (Ireland et al., 2004; Sansom et al., 2005) . Induction of recombination in the mouse small intestine was achieved after an intraperitoneal injection of b-naphthoflavone. Cre-mediated excision of exon 2, which contains the translational initiation sequence and encodes the ATP-binding site of Chk1 (Liu et al., 2000) , results in its conversion to a null allele.
To determine the extent of Cre-mediated recombination, quantitative real-time PCR (qRT-PCR) analysis of Chk1 expression was performed using RNA isolated from epithelial-enriched tissue samples ( Figure 1a ). Chk1 expression was reduced in AhCre þ Chk1 F/F mice compared with wild-type controls at day 1 postinduction (PI), and a significant decrease to around 10% of the wild-type level was seen at day 2 (Mann-Whitney U, n ¼ 3, P ¼ 0.0404), confirming that Cremediated loss of Chk1 had occurred. Although the level of recombination was high at days 1 and 2, by day 5, Chk1 RNA expression had returned to near-wild-type levels. This high level of expression was maintained at the day-21 time point. The return of Chk1 expression to wild-type levels indicates that the presence of the recombined allele is transient. Western analysis was performed to support our RNA data ( Figure 1b ). Protein was extracted from epithelial-enriched tissue samples, and the observed results were consistent with the qRT-PCR analysis. Chk1 protein levels are barely detectable at days 1 and 2, but by days 5 and 21, Chk1 levels had returned to wild-type levels. One likely explanation for this transient loss of Chk1 expression is that although a successful recombination of the Chk1 allele occurs at day 1 PI, by day 5, cells containing the Chk1 null allele are replaced with cells containing a competent unrecombined Chk1 allele. To test this hypothesis, we analysed genomic intestinal DNA for the presence of the recombined allele. PCR analysis was carried out using primers described earlier (Lam et al., 2004) that detect a 436-bp product representing the recombined Chk1 allele (Figure 1c ). From our result it is clear that the recombined allele is present at day 1 PI and also day 2, but by days 5 and 21, the AhCre þ Chk1 F/À mouse small intestine no longer contained the recombinant allele (Figure 1c , left panel). This is consistent with the replacement of intestinal cells containing the floxed Chk1 allele with cells containing the unrecombined Chk1 allele. In contrast, PCR analysis of genomic intestinal DNA isolated from AhCre þ Chk1 F/ þ mice showed that the recombined allele remained present in the Chk1 heterozygote small intestine for up to 35 weeks (Figure 1c , right panel).
Chk1 loss results in apoptosis and crypt death
To assess the phenotypic consequence of Chk1 loss in the mouse small intestine and to gain a further understanding of the kinetics involved in the loss of the recombined allele, we examined histological sections from AhCre þ Chk1 F/F mice at various time points (Figure 2a ). Histological analysis showed a clear change in the AhCre þ Chk1 F/F mouse small intestine at day 2 PI, with the cells of the intestinal crypts undergoing apoptosis (Figure 2a , Chk1 F/F d2). This increase in cell death at day 2 was independently confirmed by immunohistochemical staining with an antibody against active caspase-3 ( Figure 2b ). Day-5 histology showed virtually no apoptosis and instead showed the characteristic appearance of intestinal crypt re-population, including rapid cell proliferation and overgrowth of the crypts (Figure 2a , Chk1 F/F d5). By day 21, crypt histology had reverted back to that of wild type (Figure 2a , Chk1 F/F d21).
To quantify the increase in apoptosis and characterize any other phenotypic changes indicated by histological analysis, crypt death, mitotic index and levels of apoptosis were scored from the haematoxylin-andeosin-stained sections as described earlier (Merritt et al., 1997) . These results confirmed a 12-fold increase in apoptosis at the day-2 time point in AhCre þ Chk1 F/F mice (Figure 2c ), which was accompanied by a reduction in mitotic figures (2.7-fold, P ¼ 0.0404) and an overall decrease in the number of live crypts (30%, P ¼ 0.0404). No other time point showed a significant variation to wild type, other than an increase in bromodeoxyuridine (BrdU) uptake at days 2 and 5 in AhCre þ Chk1 F/F mice (Figure 2c ). This increase in BrdU uptake at day 2 PI (Mann-Whitney U, n ¼ 3, P ¼ 0.0404) without an increase in mitosis may reflect the ability of Chk1 null cells to synthesize DNA without being able to successfully complete mitosis. In contrast, the increase in mitosis and BrdU uptake at day 5 PI (Mann-Whitney U, n ¼ 3, P ¼ 0.0404) reflects the rapid proliferation occurring during the re-population phase of the crypt.
Histological sections from AhCre þ Chk1 F/ þ small intestine were examined and scored for crypt death, mitotic index and apoptosis ( Figure 2c ). No variation from wild type was observed over any of the time points, indicating that within the mouse small intestine, the loss of a single Chk1 allele does not result in a significant phenotype (see also Supplementary Figure 1 ). This lack of phenotype, in addition to the persistent presence of the recombined allele up to 9 months (see Figure 1c ), indicates that a heterozygous loss of Chk1 is tolerated in the mouse small intestine.
Chk1 deficiency results in an increase in DNA damage and p53 induction
The above observations show that the conditional homozygous loss of Chk1 in the mouse small intestine results in cell death. An earlier study has shown that a reduction in Chk1 levels results in genomic instability and DNA damage, which may provide a likely explanation for the increase in apoptosis (Lam et al., 2004) . To define these molecular events in the small intestine, sections were stained for phospho-H2A.X and phospho-ATM, both of which become phosphorylated Chk1 deficiency and p53-independent crypt death and intestinal compensation KR Greenow et al and activated in the presence of DNA damage (Rogakou et al., 1998; Bakkenist and Kastan, 2003) .
Our results show an increase in phospho-H2A.X and phospho-ATM staining at day 2 PI (Figures 3a and b) , indicating that AhCre þ Chk1 F/F intestinal cells are accumulating DNA damage. It is important to note that earlier reports have shown H2A.X phosphorylation to occur following apoptotic DNA fragmentation (Rogakou et al., 2000) . However, we observe the activation of H2A.X at day 1 PI (Figure 3a ), before 0.00 0.50 
the activation of caspase-3 or the appearance of apoptotic bodies, suggesting that loss of Chk1 directly causes DNA damage and that apoptosis is a secondary event that is consistent with earlier studies (Lam et al., 2004; Syljuasen et al., 2005) . In addition, immunofluorescence was carried out to further characterize the increase in phospho-H2A.X expression observed at day 1 PI. Although the increase in H2A.X phosphorylation was mainly associated with a diffuse pattern, some focal H2A.X staining was observed (see Supplementary  Figure 2 ), which is consistent with DNA damage being a consequence of Chk1 loss rather than initiated apoptosis.
Immunohistochemical staining against p53 and p21 was carried out to address any potential involvement of these apoptotic mediators. Both p21 and p53 levels were increased at day 2, coinciding with the observed increase in apoptosis (Figures 3c and d) . These results suggest that the loss of Chk1 in the mouse small intestine results in DNA damage and ultimately leads to apoptosis through a p53-dependent pathway. In contrast, immunohistochemical analysis of AhCre þ Chk1 F/ þ small intestine at all time points did not reveal increases in phospho-H2A.X (see Supplementary Figure 1 ), phospho-ATM, p53 or p21 (data not shown). In addition, the deletion of a single Chk1 allele did not sensitize cells to apoptosis following exposure to the cytotoxic drug cisplatin (see Supplementary Figure 6 ). These results, in combination with the BrdU data in Figure 2 , indicate that the loss of a single Chk1 allele has no detectable functional consequences in the mouse small intestine. This contrasts with the findings of Lam et al. (2004) in which Chk1 heterozygosity in LMECs leads to an increase in the proportion of BrdU and phospho-H2A.X staining, reflecting cell-cycle defects and genomic instability.
p53 deletion fails to rescue Chk1 null cells from apoptosis The involvement of p53 in mediating apoptosis following loss of Chk1 is unclear. Our data indicate that intestinal cell apoptosis involves the activation of both p53 and p21. In addition, avian DT40 cells lacking functional p53 can successfully replicate in the absence of Chk1 (Zachos et al., 2003) . However, both embryonic lethality and apoptosis during T-cell development following Chk1 deletion have been reported to be independent of p53 status (Liu et al., 2000; Zaugg et al., 2007) . To define the role of p53 in the apoptosis seen in the mouse intestine, we generated AhCre þ p53 F/F Chk1 F/F mice using a p53 allele described earlier (Jonkers et al., 2001) . Our results show that the loss of p53 did not alter the phenotype associated with Chk1 deletion in the mouse small intestine (Figure 4) . The levels of apoptosis between AhCre þ p53 F/F Chk1 F/F and AhCre þ p53 þ / þ Chk1 F/F were equivalent at day 2 PI, as was crypt viability, mitosis (Figure 4b ) and DNA damage (see Supplementary Figure 4 ). However, in the AhCre þ p53 F/F Chk1 F/F mice, apoptosis occurred without the induction of p53 or p21 (Figure 4a ). Overall, it is clear that although p53 is induced upon deletion of Chk1, the apoptotic phenotype of Chk1-deficient crypts is p53 independent.
In addition to the day-2 time point, we examined histological sections from AhCre þ p53 F/F Chk1 F/F mice at days 5 and 7 PI (see Supplementary Figure 5A ). Histological analysis showed that although p53 deficiency has no effect on the immediate apoptotic phenotype of Chk1 loss, p53 status does impact on the re-population that follows Chk1-dependent crypt death. At day 5, there is a marked difference in the histology of the AhCre þ p53 F/F Chk1 F/F and the AhCre þ p53 þ / þ Chk1 F/F mice, as the small intestine of the AhCre þ p53 F/F Chk1 F/F mice shows a high level of crypt death and no sign of repopulation. Re-population appears to be a later event in these mice occurring at day 7 (see Supplementary Figure  5A ). These phenotypic changes indicated by histological analysis were quantified by scoring for crypt death, mitotic index and apoptosis as described earlier (Merritt et al., 1997) . These results (see Supplementary Figures  5B-D) confirmed a significant decrease in the number of live crypts at day 5 (44.83, P ¼ 0.0113) and a moderate increase in the level of apoptosis. At day 7, it appears that the small intestine of the AhCre þ p53 F/F Chk1 F/F mice has returned to its normal state, with an increase in the number of live crypts and a decrease in apoptosis to resemble that seen in wild-type animals. From our results, it appears that the concurrent loss of p53 with Chk1 does not protect the intestine from the early wave of apoptosis but instead generates a delay in repopulation of approximately 2 days.
Earlier data have indicated a potentially important interaction of p53 and Chk1 in the cellular response to cytotoxic drugs, by which the sensitization of cells by Chk1 inhibitors may itself be optimal in a p53 null environment (Koniaras et al., 2001; Tse et al., 2007) . To investigate this interaction in vivo, we compared the levels of apoptosis in intestinal epithelial cells following Chk1 deficiency and p53-independent crypt death and intestinal compensation KR Greenow et al a dose of cisplatin. We found that although apoptosis was heavily dependent on a functional p53 allele (approximately sixfold greater in p53 wild-type animals, P ¼ 0.0012), there was no difference between the Chk1 þ / þ and Chk1 f/ þ genotypes (see Supplementary  Figure 6 ).
b-naphthoflavone injection results in Chk1 loss in the liver
In addition to the mouse small intestine, an earlier study has shown that the AhCre promoter is able to drive extensive recombination in the mouse liver (Ireland et al., 2004) . Induction of recombination was achieved through intraperitoneal injection of b-naphthoflavone, and qRT-PCR analysis showed a significant decrease in Chk1 expression in AhCre þ Chk1 F/F mice compared with wild-type controls at day 1 PI (Mann-Whitney U, n ¼ 3, P ¼ 0.0404), which was decreased to around 10% of the wild type at day 2, similar to that seen in the intestine (Mann-Whitney U, n ¼ 3, P ¼ 0.0404). However, unlike the intestine, a significant reduction in Chk1 expression Chk1 deficiency and p53-independent crypt death and intestinal compensation KR Greenow et al was maintained at day 21 and even out to a week-35 time point (Figure 5a ). In addition, PCR analysis showed the persistent presence of the recombined Chk1 allele throughout the time course of the experiment, indicating that the liver is able to tolerate the loss of Chk1 over a long period of time (Figure 5b) .
To assess the phenotypic consequence of Chk1 loss in the liver, we examined histological sections from AhCre þ Chk1 F/F mice at various time points. Our histological analysis showed no phenotypic consequence to loss of Chk1 expression in the liver (see Figure 5c ), again indicating that homozygous loss of the Chk1 allele 
Discussion
Chk1 is currently regarded as a promising drug target to enhance the sensitivity of cytotoxic drugs in cancer therapy. This is based on considerable literature generated from cell culture experiments, and there are a number of compounds currently entering clinical trials (Tse et al., 2007) . In spite of this, there is a relative paucity of information regarding the inhibition of Chk1 in vivo. The data presented in this paper add to two earlier reports analysing the functional consequences of Chk1 loss in the developing mammary gland and thymus ( Chk1 deficiency and p53-independent crypt death and intestinal compensation KR Greenow et al unlike these reports, the mouse intestine allows functional analysis of Chk1 loss in the somatic cells of a fully established adult organ system. The mouse intestine is continually turning over with replication of stem cells in the crypt and subsequent differentiation and migration to the villus tip, where they are consequently shed. It represents a relevant system to analyse Chk1 as it is biologically well defined, it represents a major site for cancer formation and is also responsible for some of the most significant drug-related side effects in chemotherapy.
The study presented in this paper clearly shows that the deletion of Chk1 in the mouse small intestine is highly traumatic. Transcript and protein are both lost within 24 h of recombination, and this loss of Chk1 results in DNA damage and apoptosis, both of which peak at 48 h. However, this Cre-mediated deletion of Chk1 is short lived. The small intestine is able to recover by recruiting epithelial stem cells in which recombination has not occurred to replace the dying Chk1deficient cells; this leads to a phase of re-population in which a rapid proliferation of intestinal epithelial cells occurs. By day 5, all cells with the recombined Chk1 allele have been eliminated, indicating that there is a strong selective disadvantage for them. This is similar to earlier reports, although in both the thymus and mammary gland there was no re-population following the loss of Chk1 but simply an inability to form functional adult tissue structures (Lam et al., 2004; Zaugg et al., 2007) . Therefore, our results, in accordance with earlier studies, indicate that Chk1 is essential for the viability of proliferating cells. In contrast, the consequence of Chk1 loss in non-proliferating cells is much less clear. Indeed, we have shown that the loss of Chk1 in the liver, a largely post-mitotic organ, is tolerated with very little effect, indicating that Chk1 function may only be required in actively cycling cells, an observation seen earlier in other post-mitotic cells (Lam et al., 2004; Zaugg et al., 2007) . However, this apparent functional redundancy in the liver is not reflected by low protein expression or increased turnover as western analysis indicates that Chk1 levels are higher than that seen in rapidly dividing intestinal epithelial cells (see Supplementary Figure 7 ).
Although we have shown that the loss of Chk1 results in p53 upregulation and apoptosis, and an earlier study has shown that only the p53-deficient DT-40 tumour cell line is able to tolerate Chk1 deletion (Zachos et al., 2003) , our results clearly show that the coincident deletion of p53 did not rescue the Chk1 null phenotype in the mouse small intestine, indicating that perhaps an alternative apoptotic pathway is activated by Chk1 loss. Indeed, an earlier study has shown that Chk1 has a protective function in the regulation of centrosomeassociated Cdk1/cyclin B and is essential for the critical timing of cell division (Kramer et al., 2004) . Therefore, the loss of Chk1 would result in unscheduled mitotic entry, which would possibly explain the p53-independent mode of cell death that we observed. Although the apoptotic phenotype remained unchanged by the loss of p53 and Chk1, our results at days 5 and 7 indicate that the additional loss of p53 does result in a significantly more severe phenotype by which the crypts of small intestine are unable to recover as quickly, due to delayed re-population.
We have also investigated the loss of a single Chk1 allele in the mouse small intestine. In contrast to earlier reports, by which Chk1 haploinsufficiency results in significant cell-cycle defects and genomic instability (Liu et al., 2000; Lam et al., 2004) , our model showed no variation from wild-type phenotype in AhCre þ Chk1 F/ þ mice relating to BrdU uptake or DNA damage. In addition, Chk1 haploinsufficiency in our model did not potentiate the cytotoxicity of a DNA-damaging agent in a p53-deficient environment, suggesting also that the loss of a single allele does not lead to a significant phenotype. Although we cannot fully explain this observation, it is possible that the requirement of Chk1 differs between tissues, or that the expression levels vary, so that the loss of a single allele may be more crucial in the mammary gland as opposed to the intestine.
Chk1 inhibitors continue to be tested in clinical trials. The findings in this and other reports are likely to have therapeutic implications. A complete ablation of Chk1 function leads to the death of replicating somatic cells. This would appear to undermine the feasibility of using inhibitors as a targeted therapy in clinical practice. However, the AhCre expression system is inducible and transient, and thus we have been able to show that providing that loss of Chk1 activity is only temporary, the functional integrity of the intestine remains intact owing to its capacity to re-populate. In addition, the in vivo consequences of partial Chk1 inhibition remain to be clarified. Although we have not observed an intestinal phenotype in Chk1 heterozygotes, the findings of Lam et al. (2004) are consistent with its role as a haploinsufficient tumour suppressor. This would clearly have implications for any drug that partially inhibits Chk1 function, especially if given over a sustained period and in combination with DNA-damaging agents. Inhibitors of Chk1 remain a viable therapeutic tool, but it is clear that a comprehensive understanding of its in vivo biology is essential to ensure a safe and effective integration with current treatment modalities.
Materials and methods

Experimental mice
Mice carrying the floxed Chk1 allele were kindly supplied by Dr Stephen J Elledge (Lam et al., 2004) . All mice were genotyped as described earlier for the targeted Chk1 allele (Lam et al., 2004) , the targeted p53 allele (Jonkers et al., 2001) , the Rosa26R allele (Soriano, 1999) and the AhCre transgene (Ireland et al., 2004) . Cre activity was induced in control and experimental mice by three consecutive intraperitoneal injections of 80 mg/kg b-naphthoflavone in 24 h. In addition, selected animals were injected with 100 mg/kg BrdU and culled 2 h after labelling or 10 mg/kg cisplatin and then culled 6 h PI. All procedures were conducted according to UK Home Office regulations.
Quantitative real-time PCR RNA was isolated from liver tissue or epithelial cells obtained by epithelial extraction (Bjerknes and Cheng, 1981 ) using a standard Trizol protocol. Reverse transcription and qRT-PCR were performed using a standard protocol. Chk1 primers were designed to the deleted exon 2 of the gene (5 0 -CTGGG ATTTGGTGCAAACTT-3 0 and 5 0 -GCCCGCTTCATGTCT ACAAT-3 0 ). Other primer sequences used were GAPDH: 5 0 -CACTGAGCATCTCCCTCACA-3 0 and 5 0 -GTGGGTGCAG CGAACTTTAT-3 0 ; and b-actin: 5 0 -ACAGCTTCTTTGCAG CTCCTT-3 0 and 5 0 -TGGTAACAATGCCATGTTCAAT-3 0 .
Western analysis
Protein was isolated from epithelial-enriched pellets (Bjerknes and Cheng, 1981) , and subsequent protein analysis, SDSpolyacrylamide gel electrophoresis and western blotting were carried out following standard protocols. Chk1 mouse monoclonal antibody (Abgent, Abingdon, UK) was used at a dilution of 1:1000 and mouse monoclonal b-actin (Sigma, Poole, UK) at a dilution of 1:12 000.
Recombination analysis
Detection of the recombined allele in wild-type (AhCre þ Chk1 þ / þ ) and experimental (AhCre þ Chk1 F/ þ and AhCre þ Chk1 F/À ) mice was carried out using a PCR-based analysis. DNA was extracted from 2 mm sections of small intestine or liver and recombinant DNA was detected as described earlier (Lam et al., 2004) . Primers against the wildtype APC allele (Shibata et al., 1997) were used as a control.
Histology and immunohistochemistry
Intestinal and liver tissue was fixed in ice-cold 10% neutral buffered formalin for no longer than 24 h before being processed into paraffin blocks according to standard procedures. Tissue sections (5 mm) were either stained using haematoxylin and eosin for histological analysis or were used for immunohistochemistry. The following antibodies were used for immunohistochemistry: anti-ATM (1:300; Rockland, Gilbertsville, PA, USA), anti-caspase-3 (1:750; R&D systems, Abingdon, UK), mouse anti-p53 (1:50; Labvision, Freemont, CA, USA), mouse anti-H2A.X (Ser139) (1:200; Upstate/ Millipore, Livingston, UK), mouse anti-BrdU (1:100; Becton Dickinson, Oxford, UK) and rabbit anti-p21 (1:500; Santa Cruz, Santa Cruz, CA, USA).
Immunofluorescence microscopy
Immunofluorescence was carried out using the above method described for immunohistochemistry using the Alexa Fluor 488 goat anti-mouse IgG secondary antibody (1:300; Invitrogen, Inchinnan, UK). Stained tissue sections were scanned on a Leica TCS SP2 AOBS spectral confocal laser-scanning microscope (Leica, Germany) running Leica Confocal Software. Representative regions of tissue were scanned using Â 40 and Â 63 oil immersion objectives, with appropriate excitation and emission settings for simultaneous recordings of DAPI (Ex. Max: 358; Em. Max: 461) and Alexa 488 (Ex. Max: 488; Em. Max: 519). Optical sections were sampled at approximately 0.50 m intervals and maximum intensity-type reconstructions then prepared from the resultant image stacks.
